NZ739876A - Process for preparing parp inhibitor, crystalline forms, and uses thereof - Google Patents
Process for preparing parp inhibitor, crystalline forms, and uses thereofInfo
- Publication number
- NZ739876A NZ739876A NZ739876A NZ73987616A NZ739876A NZ 739876 A NZ739876 A NZ 739876A NZ 739876 A NZ739876 A NZ 739876A NZ 73987616 A NZ73987616 A NZ 73987616A NZ 739876 A NZ739876 A NZ 739876A
- Authority
- NZ
- New Zealand
- Prior art keywords
- crystalline forms
- preparing
- parp inhibitor
- preparing parp
- compound
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
- 229940126062 Compound A Drugs 0.000 abstract 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 abstract 2
- DENYZIUJOTUUNY-MRXNPFEDSA-N (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one Chemical compound FC=1C=C2C=3C=4C(CN5[C@@](C4NC3C1)(CCC5)C)=NNC2=O DENYZIUJOTUUNY-MRXNPFEDSA-N 0.000 abstract 1
- 229940125941 PARP1/2 inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015088003 | 2015-08-25 | ||
| PCT/CN2016/096200 WO2017032289A1 (en) | 2015-08-25 | 2016-08-22 | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ739876A true NZ739876A (en) | 2022-09-30 |
Family
ID=58099633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ739876A NZ739876A (en) | 2015-08-25 | 2016-08-22 | Process for preparing parp inhibitor, crystalline forms, and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10457680B2 (enExample) |
| EP (1) | EP3341375B1 (enExample) |
| JP (1) | JP6940039B2 (enExample) |
| KR (1) | KR20180041748A (enExample) |
| CN (2) | CN107922425B (enExample) |
| AU (1) | AU2016312011B2 (enExample) |
| BR (1) | BR112018003634B1 (enExample) |
| CA (1) | CA2994895A1 (enExample) |
| EA (1) | EA037366B1 (enExample) |
| IL (2) | IL296835A (enExample) |
| MX (1) | MX385450B (enExample) |
| NZ (1) | NZ739876A (enExample) |
| TW (1) | TWI736550B (enExample) |
| WO (1) | WO2017032289A1 (enExample) |
| ZA (1) | ZA201800765B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101716012B1 (ko) | 2011-12-31 | 2017-03-13 | 베이진 엘티디 | Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 다이하이드로다이아제피노카르바졸론 |
| AU2016312011B2 (en) | 2015-08-25 | 2021-02-04 | Beigene, Ltd. | Process for preparing Parp inhibitor, crystalline forms, and uses thereof |
| US11202782B2 (en) | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
| CN110392687B (zh) * | 2017-02-28 | 2022-08-02 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途 |
| US12121518B2 (en) | 2017-03-09 | 2024-10-22 | The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College | PARP-1 and methods of use thereof |
| WO2018165615A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| AU2018302999A1 (en) * | 2017-07-17 | 2020-01-30 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy |
| WO2019220390A1 (en) | 2018-05-18 | 2019-11-21 | Novartis Ag | Crystalline forms of a tlr7/tlr8 inhibitor |
| WO2019228499A1 (en) * | 2018-06-01 | 2019-12-05 | Beigene, Ltd. | Maintenance therapy of a parp inhibitor in treating gastric cancer |
| USD926356S1 (en) * | 2019-03-14 | 2021-07-27 | Tuanfang Liu | Battery for electronic cigarette |
| CN113004279B (zh) * | 2019-05-10 | 2023-01-06 | 百济神州(苏州)生物科技有限公司 | 一种控制含parp抑制剂倍半水合物产物的含水量的方法 |
| CN113402502B (zh) * | 2019-05-16 | 2022-10-14 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体制备的物料组合体系 |
| CN111171001B (zh) * | 2019-05-16 | 2022-04-29 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂中间体的结晶方法 |
| CA3141770A1 (en) | 2019-05-31 | 2020-12-03 | Beigene, Ltd. | Parp inhibitor pellet preparation and preparation process therefor |
| CN112007011B (zh) * | 2019-05-31 | 2024-07-23 | 百济神州(苏州)生物科技有限公司 | 一种parp抑制剂微丸胶囊及其制备工艺 |
| WO2021046014A1 (en) | 2019-09-03 | 2021-03-11 | Teva Czech Industries S.R.O | Solid state forms of pamiparib and process for preparation thereof |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1140936B1 (en) | 1999-01-11 | 2004-03-17 | Agouron Pharmaceuticals, Inc. | Tricyclic inhibitors of poly(adp-ribose) polymerases |
| US6887996B2 (en) * | 2000-12-01 | 2005-05-03 | Guilford Pharmaceuticals Inc. | Compounds and their use |
| EA009337B1 (ru) * | 2003-01-09 | 2007-12-28 | Пфайзер Инк. | Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии |
| HUE035295T2 (en) | 2008-08-06 | 2018-05-02 | Medivation Technologies Inc | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| KR101716012B1 (ko) | 2011-12-31 | 2017-03-13 | 베이진 엘티디 | Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 다이하이드로다이아제피노카르바졸론 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| TWI726608B (zh) | 2014-07-03 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 抗pd-l1抗體及其作為治療及診斷之用途 |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| AU2016312011B2 (en) | 2015-08-25 | 2021-02-04 | Beigene, Ltd. | Process for preparing Parp inhibitor, crystalline forms, and uses thereof |
| US11202782B2 (en) * | 2016-09-27 | 2021-12-21 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors |
| CN110392687B (zh) * | 2017-02-28 | 2022-08-02 | 百济神州(苏州)生物科技有限公司 | 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途 |
| AU2018302999A1 (en) * | 2017-07-17 | 2020-01-30 | Beigene, Ltd. | Treatment cancers using a combination comprising PARP inhibitors, temozolomide and/or radiation therapy |
| CN113004279B (zh) * | 2019-05-10 | 2023-01-06 | 百济神州(苏州)生物科技有限公司 | 一种控制含parp抑制剂倍半水合物产物的含水量的方法 |
-
2016
- 2016-08-22 AU AU2016312011A patent/AU2016312011B2/en not_active Ceased
- 2016-08-22 US US15/753,993 patent/US10457680B2/en active Active
- 2016-08-22 IL IL296835A patent/IL296835A/en unknown
- 2016-08-22 EA EA201890547A patent/EA037366B1/ru not_active IP Right Cessation
- 2016-08-22 NZ NZ739876A patent/NZ739876A/en not_active IP Right Cessation
- 2016-08-22 KR KR1020187008548A patent/KR20180041748A/ko not_active Ceased
- 2016-08-22 JP JP2018510352A patent/JP6940039B2/ja not_active Expired - Fee Related
- 2016-08-22 IL IL257442A patent/IL257442B2/en unknown
- 2016-08-22 BR BR112018003634-0A patent/BR112018003634B1/pt not_active IP Right Cessation
- 2016-08-22 CN CN201680048637.5A patent/CN107922425B/zh active Active
- 2016-08-22 CN CN202011223061.6A patent/CN112521390A/zh active Pending
- 2016-08-22 MX MX2018002322A patent/MX385450B/es unknown
- 2016-08-22 EP EP16838548.2A patent/EP3341375B1/en not_active Not-in-force
- 2016-08-22 WO PCT/CN2016/096200 patent/WO2017032289A1/en not_active Ceased
- 2016-08-22 CA CA2994895A patent/CA2994895A1/en active Pending
- 2016-08-24 TW TW105127160A patent/TWI736550B/zh not_active IP Right Cessation
-
2018
- 2018-02-06 ZA ZA201800765A patent/ZA201800765B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA037366B1 (ru) | 2021-03-18 |
| EP3341375A4 (en) | 2019-01-16 |
| IL257442B2 (en) | 2023-03-01 |
| ZA201800765B (en) | 2019-10-30 |
| EP3341375A1 (en) | 2018-07-04 |
| AU2016312011A1 (en) | 2018-03-08 |
| EA201890547A1 (ru) | 2018-07-31 |
| IL257442A (en) | 2018-04-30 |
| BR112018003634A2 (en) | 2018-11-21 |
| CA2994895A1 (en) | 2017-03-02 |
| TWI736550B (zh) | 2021-08-21 |
| US10457680B2 (en) | 2019-10-29 |
| US20190177325A1 (en) | 2019-06-13 |
| TW201718586A (zh) | 2017-06-01 |
| AU2016312011B2 (en) | 2021-02-04 |
| CN107922425A (zh) | 2018-04-17 |
| CN112521390A (zh) | 2021-03-19 |
| MX385450B (es) | 2025-03-18 |
| WO2017032289A1 (en) | 2017-03-02 |
| JP6940039B2 (ja) | 2021-09-22 |
| KR20180041748A (ko) | 2018-04-24 |
| CN107922425B (zh) | 2021-06-01 |
| IL257442B (en) | 2022-11-01 |
| EP3341375B1 (en) | 2022-04-13 |
| IL296835A (en) | 2022-11-01 |
| BR112018003634A8 (pt) | 2023-01-17 |
| BR112018003634B1 (pt) | 2023-11-21 |
| MX2018002322A (es) | 2018-04-11 |
| JP2018528199A (ja) | 2018-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX385450B (es) | Procedimiento para la preparación de un inhibidor de poli(adp-ribosa)polimerasa, formas cristalinas, y usos del mismo. | |
| EP4585268A3 (en) | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same | |
| MX383935B (es) | Amidas heterocíclicas como inhibidores de cinasa. | |
| SA518400547B1 (ar) | مشتقات بيرازولو بيريميدين كمثبط كيناز | |
| WO2016011390A8 (en) | Irak4 inhibiting agents | |
| EP3828186A3 (en) | Pyrimidinones as factor xia inhibitors | |
| MY202022A (en) | Pyrrolotriazine compounds as tam inhibitors | |
| MX368496B (es) | Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. | |
| NZ716392A (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
| PL3322706T3 (pl) | Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret | |
| WO2016044556A3 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| HK1220355A1 (zh) | Mk2抑制劑和其用途 | |
| AU2015292632B2 (en) | Aldosterone synthase inhibitors | |
| WO2016079751A3 (en) | A process for preparation of vortioxetine and polymorphs thereof | |
| PH12019501022A1 (en) | Pyrazolopyrimidine compounds and methods of use thereof | |
| JOP20190163B1 (ar) | منشط nrf2 | |
| MX2017008280A (es) | Proceso para elaborar cenicriviroc y analogos relacionados. | |
| AU2017257755A1 (en) | Benzoylglycine derivatives and methods of making and using same | |
| PH12019500370A1 (en) | Triazolopyrazinone derivative useful as a human pde1 inhibitor | |
| MX385672B (es) | Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-amina sustituida. | |
| MX369451B (es) | Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas. | |
| MX2016013439A (es) | Formas solidas de un compuesto farmaceuticamente activo. | |
| WO2016164295A3 (en) | Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors | |
| MX2019012765A (es) | Proceso para la fabricacion de la forma alfa de vortioxetina hbr. | |
| GB2564185A (en) | Process for the preparation of derivatives of benzodioxole |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 22 AUG 2024 BY ACUMASS Effective date: 20230720 |
|
| LAPS | Patent lapsed |